Multiply Labs raised a $75 million Series B led by NantWorks. AstraZeneca, Lingotto and Teradyne also joined the round. The company automates complex drug manufacturing with robotics. Its clusters cut cost per dose by 74% and boost throughput up to 100 times. The system is autonomous and GMP-compliant. It integrates with existing instruments without new facilities. The platform covers cell and gene therapy, antibodies, viral vectors and mRNA. Pharmaceutical companies own and operate the clusters themselves. The funds will expand capacity, accelerate the product roadmap and scale the team.
What changed
Drug manufacturing timelines remained largely unchanged despite AI accelerating drug discovery.
What it unlocks
Scaling robotic manufacturing capacity to turn AI-discovered drugs into patient treatments faster.
- $75 million Series B
- $100 million total raised
- 74% reduction in cost per dose
- 100x more throughput
Sources